Survival Outcomes of Gynecological Oncology Patients at Assiut University: A Retrospective Study (2022-2025)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Assiut University
- Enrollment
- 200
- Primary Endpoint
- Overall Survival
Study Overview
Brief Summary
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.
Detailed Description
The study aims to evaluate overall survival (OS) and progression-free survival (PFS) of patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancers) and treated at Assiut University Hospital from January 1, 2022, to December 31, 2025. Using retrospective medical records and pathology reports, the study will analyze demographic, clinical, and treatment-related variables to identify factors influencing survival outcomes. Assiut University is a tertiary care center in a low-resource setting; thus, the study will also assess adherence to international oncology guidelines (e.g., ESMO, ASCO) and compare local survival rates with international standards. Statistical methods include Kaplan-Meier survival analysis and Cox proportional hazards modeling.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •- Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal)
- •Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025
- •All age groups included
Exclusion Criteria
- •- Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract
- •Patients with incomplete medical records (e.g., missing pathology reports or treatment details)
- •Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)
Outcomes
Primary Outcomes
Overall Survival
Time Frame: 4 years
Overall survival (OS) is defined as the duration of time from the date of cancer diagnosis or initiation of treatment until death from any cause. Patients will be censored at the date of last follow-up if alive at study end. This outcome will provide a direct estimate of survival rates among gynecological oncology patients treated at Assiut University Hospital.
Secondary Outcomes
No secondary outcomes reported
Investigators
Esraa Mohamed Farouk
Resident at Obstetric and Gynecology Department
Assiut University